开发一种无创检测前列腺癌的排尿尿液检测方法:一项先导研究
OBJECTIVE: To validate a hypothesis that prostate cancer can be detected non-invasively by a simple and reliable assay by targeting genomic VPAC receptors expressed on malignant prostate cancer cells shed in voided urine.…
要点
- 排尿尿液TP4303检测在前列腺癌男性中检出VPAC阳性细胞的比例为98.6%(141例中)。
- 10例良性前列腺增生男性均未检出VPAC阳性细胞。
核心结论
- 这些初步数据令人鼓舞,值得进一步评估该检测作为无创检测前列腺癌的简单可靠工具。
研究设计与样本
- 先导研究,经机构审查委员会豁免批准使用去标识化的丢弃样本。
- 对就诊于泌尿科门诊的207例患者(176名男性、31名女性,年龄≥21岁)按标准诊疗留取的尿液进行细胞离心,用TP4303和DAPI处理后显微镜观察。
主要发现
- 141例有前列腺癌诊断的男性中98.6%检出VPAC阳性细胞,10例良性前列腺增生男性中无一检出。
- 56例「正常」患者中62.5%(35例,10男25女)VPAC细胞阴性,19.6%(11例,11男0女)有VPAC阳性细胞,17.8%(10例,4男6女)因尿中结晶过多无法判读。
- 受体阻断实验和荧光激活细胞分选(FACS)分析证实VPAC受体存在,基因谱检查证实表达VPAC受体的细胞为恶性前列腺癌细胞。
局限性
- 作者指出数据有限。
- 尿液标本仅标注性别和就诊诊断,无个人健康标识或其他临床数据。
- 作者结论为初步数据令人鼓舞,需进一步评估该检测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To validate a hypothesis that prostate cancer can be detected non-invasively by a simple and reliable assay by targeting genomic VPAC receptors expressed on malignant prostate cancer cells shed in voided urine. PATIENTS/SUBJECTS AND METHODS: VPAC receptors were targeted with a specific biomolecule, TP4303, developed in our laboratory. With an Institutional Review Board exempt approval of use of de-identified discarded samples, an aliquot of urine collected as a standard of care, from patients presenting to the urology clinic (207 patients, 176 men and 31 women, aged ≥21 years) was cytospun. The cells were fixed and treated with TP4303 and 4,6-diamidino-2-phenylindole (DAPI). The cells were then observed under a microscope and cells with TP4303 orange fluorescence around the blue (DAPI) nucleus were considered 'malignant' and those only with a blue nucleus were regarded as 'normal'. VPAC presence was validated using receptor blocking assay and cell malignancy was confirmed by prostate cancer gene profile examination. RESULTS: The urine specimens were labelled only with gender and presenting diagnosis, with no personal health identifiers or other clinical data. The assay detected VPAC positive cells in 98.6% of the men with a prostate cancer diagnosis (141), and none of the 10 men with benign prostatic hyperplasia. Of the 56 'normal' patients, 62.5% (35 patients, 10 men and 25 women) were negative for VPAC cells; 19.6% (11, 11 men and no women) had VPAC positive cells; and 17.8% (10, four men and six women) were uninterpretable due to excessive crystals in the urine. Although data are limited, the sensitivity of the assay was 99.3% with a confidence interval (CI) of 96.1-100% and the specificity was 100% with a CI of 69.2-100%. Receptor blocking assay and fluorescence-activated cell sorting (FACS) analyses demonstrated the presence of VPAC receptors and gene profiling examinations confirmed that the cells expressing VPAC receptors were malignant prostate cancer cells. CONCLUSION: These preliminary data are highly encouraging and warrant further evaluation of the assay to serve as a simple and reliable tool to detect prostate cancer non-invasively.
引用
- Trabulsi EJ, Tripathi SK, Gomella L, et al. Development of a voided urine assay for detecting prostate cancer non-invasively: a pilot study. BJU Int. 2017. PMID: 28075510. doi:10.1111/bju.13775
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。